EUVIMEDOpdag EUVIMED
Multizentrische Studie

Prognostic Effect of KELIM Score of Prostate‐Specific Antigen in Hormone‐Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways

Yusuf Ilhan iD, Murat Araz iD, Ali Fuat Gurbuz iD, Semiha Urvay iD, Muslih Urun iD, Berrak Mermit Ercek iD, Ozden Ozilice iD, Onur Yazdan Balcik iD, Canan Yildiz iD, Hacer Demir iD, Ismail Beypinar iD

The Prostate · 2026

DOI: 10.1002/pros.70098 ↗

At a glance

Multizentrische Studie in The Prostate, 2026. Written by Yusuf Ilhan and 10 co-authors. Institution: Department of Medical Oncology, Antalya City Hospital, Antalya, Turkey. Major MEDLINE topics: Prostate-Specific Antigen, Androgen Receptor Antagonists, Phenylthiohydantoin, Prostatic Neoplasms, Castration-Resistant. Cited 1 times so far (Crossref); 16 references. Funded by: The authors received no specific funding for this work..

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

The prognostic value of the PSA ELIMination rate constant K (PRO‐KELIM) score was investigated in patients with metastatic castration‐sensitive prostate cancer (mCSPC) treated with novel androgen receptor inhibitors.

Methods

This multicenter retrospective study included 160 patients diagnosed with prostate adenocarcinoma between 2011 and 2024 who received enzalutamide or abiraterone during the mCSPC and had at least three PSA measurements within the first 100 days of treatment. The patients were categorized into favorable (PRO‐KELIM ≥ 1.0) and unfavorable (PRO‐KELIM < 1.0) groups. Progression‐free survival (PFS) and overall survival (OS) were analyzed using the Kaplan–Meier survival analysis and Cox regression.

Results

Median PFS was significantly higher in the favorable group than in the unfavorable group (not reached vs. 40.0 months, p < 0.001). The estimated 2‐year PFS rates in the favorable and unfavorable groups were 78% and 52%, respectively. In multivariate analyses, a high PRO‐KELIM score (HR 2.99; 95% CI 1.35–6.66, p = 0.007) and good initial response to treatment ( p = 0.001) were independent favorable prognostic factors for PFS. The median OS did not differ significantly between the groups ( p = 0.27). PRO‐KELIM score was not an independent prognostic factor for OS ( p = 0.76).

Conclusion

These findings suggest that the PRO‐KELIM score can be a valuable prognostic tool in the mCSPC to assess early treatment response and predict disease progression.

Subjects

MeSH terms (MEDLINE)

Prostate-Specific AntigenAndrogen Receptor AntagonistsPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsAdenocarcinomaHumansMaleRetrospective StudiesAgedNitrilesBenzamidesPrognosisMiddle AgedAged, 80 and overAndrostenesProgression-Free Survival

Author keywords

Androgen receptor inhibitorsMetastatic castration‐sensitive prostate cancerProstate‐specific antigen (PSA)The ELIMination rate constant K (KELIM)

Substances

Prostate-Specific AntigenNitrilesBenzamidesenzalutamideAndrogen Receptor AntagonistsPhenylthiohydantoinabirateroneAndrostenes

Authors and institutions

  • Department of Medical Oncology, Antalya City Hospital, Antalya, Turkey.
  • Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey.
  • Department of Medical Oncology, Kayseri Acıbadem Hospital, Kayseri, Turkey.
  • Department of Medical Oncology, Van Yüzüncü Yıl University, Van, Turkey.
  • Alanya District Health Directorate, Alanya, Antalya, Turkey.
  • Department of Medical Oncology, Alaaddin Keykubat University, Antalya, Turkey.

ORCID profiles: Yusuf Ilhan, Murat Araz, Ali Fuat Gurbuz, Semiha Urvay, Muslih Urun, Berrak Mermit Ercek, Ozden Ozilice, Onur Yazdan Balcik, Canan Yildiz, Hacer Demir, Ismail Beypinar

Funding

  • The authors received no specific funding for this work.

Cite

APA

Ilhan, Y., Araz, M., Gurbuz, A. F., Urvay, S., Urun, M., Mermit Ercek, B., Ozilice, O., Balcik, O. Y., Yildiz, C., Demir, H., & Beypinar, I. (2026). Prognostic Effect of KELIM Score of Prostate‐Specific Antigen in Hormone‐Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways. The Prostate. https://doi.org/10.1002/pros.70098

Vancouver

Ilhan Y, Araz M, Gurbuz AF, Urvay S, Urun M, Mermit Ercek B, et al. Prognostic Effect of KELIM Score of Prostate‐Specific Antigen in Hormone‐Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways. The Prostate. 2026. doi:10.1002/pros.70098

BibTeX
@article{Ilhan2026,
  author = {Ilhan, Yusuf and Araz, Murat and Gurbuz, Ali Fuat and Urvay, Semiha and Urun, Muslih and Mermit Ercek, Berrak and Ozilice, Ozden and Balcik, Onur Yazdan and Yildiz, Canan and Demir, Hacer and Beypinar, Ismail},
  title = {Prognostic Effect of KELIM Score of Prostate‐Specific Antigen in Hormone‐Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways},
  journal = {The Prostate},
  year = {2026},
  doi = {10.1002/pros.70098}
}
Start for free →